Item 5.02(e) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 21, 2022, the board of directors of Blueprint Medicines Corporation (the "Company") amended and restated the Blueprint Medicines Corporation 2020 Inducement Plan (the "A&R 2020 Inducement Plan") to increase the number of shares of the Company's common stock available for issuance pursuant to equity awards granted under the A&R 2020 Inducement Plan from 1,000,000 shares to 2,500,000 shares (the "Share Reserve"). In accordance with Nasdaq Listing Rule 5635(c)(4), the Company did not seek approval of the A&R 2020 Inducement Plan by its stockholders. Other than the increase in the Share Reserve, the terms and conditions of the A&R 2020 Inducement Plan were not changed.

The foregoing is a brief description of the material terms of the A&R 2020 Inducement Plan and is qualified in its entirety by reference to the full text of the A&R 2020 Inducement Plan, filed as Exhibit 10.1 to this Current Report on Form 8-K.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting of Stockholders on June 21, 2022 (the "Annual Meeting"). The following is a summary of the matters voted on at that meeting.





   1. The Company's stockholders elected Jeffrey W. Albers, Mark Goldberg, M.D.
      and Nicholas Lydon, Ph.D. as Class I directors, each to serve for a
      three-year term expiring at the 2025 annual meeting of stockholders and
      until his successor has been duly elected and qualified. The results of the
      stockholders' vote with respect to the election of such Class I directors
      were as follows:




                                                           Broker
                          Votes            Votes            Non-
Name                       For            Withheld          Votes
Jeffrey W. Albers       38,338,820       15,880,558       1,984,429
Mark Goldberg, M.D.     21,917,758       32,301,620       1,984,429
Nicholas Lydon, Ph.D.   32,673,870       21,545,508       1,984,429




   2. The Company's stockholders approved the non-binding, advisory vote on the
      compensation paid to its named executive officers. The results of the
      stockholders' non-binding, advisory vote with respect to compensation paid
      to the Company's named executive officers were as follows:




  Votes       Votes
   For       Against    Votes Abstaining   Broker Non-Votes
53,277,135   916,091         26,152           1,984,429




   3. The Company's stockholders ratified the appointment of Ernst & Young LLP as
      the Company's independent registered public accounting for the fiscal year
      ending December 31, 2022. The results of the stockholders' vote with
      respect to such ratification were as follows:




  Votes       Votes
   For       Against    Votes Abstaining
55,836,831   343,817         23,159

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.


Exhibit No.    Description
  10.1           Blueprint Medicines Corporation Amended and Restated 2020
               Inducement Plan
104            Cover Page Interactive Data File (embedded within the Inline XBRL
               document and incorporated as Exhibit 101)

© Edgar Online, source Glimpses